aspirin has been researched along with HIV Coinfection in 45 studies
Aspirin: The prototypical analgesic used in the treatment of mild to moderate pain. It has anti-inflammatory and antipyretic properties and acts as an inhibitor of cyclooxygenase which results in the inhibition of the biosynthesis of prostaglandins. Aspirin also inhibits platelet aggregation and is used in the prevention of arterial and venous thrombosis. (From Martindale, The Extra Pharmacopoeia, 30th ed, p5)
acetylsalicylate : A benzoate that is the conjugate base of acetylsalicylic acid, arising from deprotonation of the carboxy group.
acetylsalicylic acid : A member of the class of benzoic acids that is salicylic acid in which the hydrogen that is attached to the phenolic hydroxy group has been replaced by an acetoxy group. A non-steroidal anti-inflammatory drug with cyclooxygenase inhibitor activity.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Inflammation contributes to this risk but the role of lipid mediators, with central roles in inflammation, in HIV infection remain to be established; further aspirin reduces CVD risk in the general population through production of some of these anti-inflammatory lipid mediators, but they have not been studied in PWH." | 9.69 | Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention. ( Aberg, JA; Brown, TT; Dalli, J; Funderburg, N; Gupta, A; Hunt, PW; Kitch, D; Moisi, D; O'Brien, MP; Shivakoti, R; Tien, PC, 2023) |
| "This retrospective, cross-sectional study evaluated whether HIV-infected patients received aspirin and statins for the primary prevention of myocardial infarction and stroke." | 7.83 | Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection. ( Park, TE; Sharma, R; Yusuff, J, 2016) |
| "We conducted a phase 2, open-label, parallel-design, randomized, controlled trial to assess the safety of high-dose rifampicin, linezolid, and high-dose aspirin in HIV-associated TBM." | 5.69 | A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial. ( Aziz, S; Banderker, IA; Black, J; Bremer, M; Candy, S; Crede, T; Daroowala, R; Davis, AG; Denti, P; Goliath, R; Jackson, A; Jason Liang, C; Kadernani, Y; Koekemoer, S; Lai Sai, L; Lai, RPJ; Maartens, G; Maxebengula, M; Meintjes, G; Moosa, MS; Naude, J; Offiah, C; Raubenheimer, P; Sihoyiya, T; Stegmann, S; Stek, C; Szymanski, P; Vallie, Y; Vorster, I; Wahl, G; Wasserman, S; Wilkinson, RJ, 2023) |
| " Inflammation contributes to this risk but the role of lipid mediators, with central roles in inflammation, in HIV infection remain to be established; further aspirin reduces CVD risk in the general population through production of some of these anti-inflammatory lipid mediators, but they have not been studied in PWH." | 5.69 | Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention. ( Aberg, JA; Brown, TT; Dalli, J; Funderburg, N; Gupta, A; Hunt, PW; Kitch, D; Moisi, D; O'Brien, MP; Shivakoti, R; Tien, PC, 2023) |
| "Aspirin and atorvastatin could play a role in targeting HIV-associated inflammation." | 5.69 | An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV. ( Baker, JV; Gorelick, RJ; Krishnan, S; Laidlaw, E; Lisco, A; Manion, M; Migueles, SA; Mystakelis, HA; Poole, A; Rupert, A; Sereti, I; Welker, JL; Wilson, E, 2023) |
| "Acute coronary syndrome patients infected with HIV (n = 80) were matched to ACS patients without HIV (n = 160) on age, sex, diabetes, and DAPT (aspirin 100%, clopidogrel 68%, prasugrel 31%, ticagrelor 1%)." | 3.85 | Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study. ( Boccara, F; Boyd, A; Brugier, D; Cohen, A; Collet, JP; Curjol, A; Galier, S; Hauguel-Moreau, M; Hulot, JS; Kerneis, M; Montalescot, G; Salem, JE; Silvain, J, 2017) |
| "This retrospective, cross-sectional study evaluated whether HIV-infected patients received aspirin and statins for the primary prevention of myocardial infarction and stroke." | 3.83 | Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection. ( Park, TE; Sharma, R; Yusuff, J, 2016) |
| "Coronary thrombosis is known to provoke myocardial infarctions, but whether PWH have elevated thrombotic propensity is unknown." | 2.90 | Targeting thrombogenicity and inflammation in chronic HIV infection. ( Aberg, JA; Badimon, JJ; Cavanagh, K; Escolar, G; Heyison, A; O'Brien, MP; Okoroafor, I; Rodriguez, JC; Rodriguez-Caprio, G; Weinberg, A; Zafar, MU, 2019) |
| "Aspirin has antiplatelet and immunomodulatory properties." | 2.78 | Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. ( Aberg, JA; Berger, JS; Bhardwaj, N; Cavanagh, K; Gettenberg, G; Hu, L; Merolla, M; Montenont, E; Nardi, MA; O'Brien, M; Valdes, V, 2013) |
| "Aspirin and selenium have been shown in vitro and in vivo to inhibit HIV production through inhibition of the transcription factor, the nuclear factor kappa binding (NF-eB)." | 2.73 | Selenium and aspirin in people living with HIV and AIDS in Nigeria. ( Adediran, IA; Akinola, NO; Armistead, H; Durosinmi, MA; Elujoba, AA; Falola, OL; Irinoye, O; Muraina, HA; Odusoga, OL; Ogun, SA; Olasode, OA; Onayemi, O, 2008) |
| "Cerebral vasculitis caused by neurosyphilis is a re-emerging problem with diagnostic and treatment issues, especially for human immunodeficiency virus patients." | 1.48 | Treatment of Syphilis-Associated Cerebral Vasculitis: Reappearance of an Old Question. ( Dion, J; Dupin, N; Le Jeunne, C; Mageau, A; Mouthon, L; Régent, A; Rodriguez-Régent, C, 2018) |
| " Twenty-seven men were dosed with 100 mg desipramine (a weak base) and 975 mg aspirin (a weak acid) and ejaculated their semen in 1 pass across 5 compartments of a collection device 2." | 1.35 | Noninvasive quantitation of drug concentration in prostate and seminal vesicles: improvement and validation with desipramine and aspirin. ( Caffo, B; Cao, YJ; Choi, L; Fuchs, EJ; Hendrix, CW; Radebaugh, CL, 2008) |
| "The occurrence of Kawasaki disease is unusual in adults." | 1.33 | Kawasaki-like syndrome possibly associated with immune reconstitution inflammatory syndrome in an HIV-positive patient. ( Crespo, A; Menezes, L; Velez, AP, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (11.11) | 18.2507 |
| 2000's | 12 (26.67) | 29.6817 |
| 2010's | 18 (40.00) | 24.3611 |
| 2020's | 10 (22.22) | 2.80 |
| Authors | Studies |
|---|---|
| Pezel, T | 1 |
| Paim, LR | 1 |
| Coelho-Filho, OR | 1 |
| Mwakyandile, T | 1 |
| Shayo, G | 1 |
| Mugusi, S | 1 |
| Sunguya, B | 1 |
| Sasi, P | 1 |
| Moshiro, C | 1 |
| Mugusi, F | 1 |
| Lyamuya, E | 1 |
| Lajoie, J | 3 |
| Kowatsch, MM | 1 |
| Mwangi, LW | 1 |
| Boily-Larouche, G | 2 |
| Oyugi, J | 2 |
| Chen, Y | 2 |
| Kimani, M | 2 |
| Ho, EA | 2 |
| Kimani, J | 2 |
| Fowke, KR | 3 |
| Maitre, T | 1 |
| Bonnet, M | 1 |
| Calmy, A | 1 |
| Raberahona, M | 1 |
| Rakotoarivelo, RA | 1 |
| Rakotosamimanana, N | 1 |
| Ambrosioni, J | 1 |
| Miró, JM | 1 |
| Debeaudrap, P | 1 |
| Muzoora, C | 1 |
| Davis, A | 1 |
| Meintjes, G | 3 |
| Wasserman, S | 3 |
| Wilkinson, R | 1 |
| Eholié, S | 1 |
| Nogbou, FE | 1 |
| Calvo-Cortes, MC | 1 |
| Chazallon, C | 1 |
| Machault, V | 1 |
| Anglaret, X | 1 |
| Bonnet, F | 1 |
| Davis, AG | 2 |
| Stek, C | 2 |
| Maxebengula, M | 2 |
| Jason Liang, C | 2 |
| Stegmann, S | 2 |
| Koekemoer, S | 2 |
| Jackson, A | 2 |
| Kadernani, Y | 2 |
| Bremer, M | 2 |
| Daroowala, R | 2 |
| Aziz, S | 2 |
| Goliath, R | 2 |
| Lai Sai, L | 2 |
| Sihoyiya, T | 2 |
| Denti, P | 2 |
| Lai, RPJ | 2 |
| Crede, T | 2 |
| Naude, J | 2 |
| Szymanski, P | 2 |
| Vallie, Y | 2 |
| Banderker, IA | 2 |
| Moosa, MS | 2 |
| Raubenheimer, P | 2 |
| Candy, S | 3 |
| Offiah, C | 2 |
| Wahl, G | 2 |
| Vorster, I | 2 |
| Maartens, G | 2 |
| Black, J | 2 |
| Wilkinson, RJ | 2 |
| Dalli, J | 1 |
| Kitch, D | 1 |
| O'Brien, MP | 2 |
| Hunt, PW | 1 |
| Funderburg, N | 1 |
| Moisi, D | 1 |
| Gupta, A | 1 |
| Brown, TT | 1 |
| Tien, PC | 1 |
| Aberg, JA | 3 |
| Shivakoti, R | 1 |
| Mystakelis, HA | 1 |
| Wilson, E | 1 |
| Laidlaw, E | 1 |
| Poole, A | 1 |
| Krishnan, S | 1 |
| Rupert, A | 1 |
| Welker, JL | 1 |
| Gorelick, RJ | 1 |
| Lisco, A | 1 |
| Manion, M | 1 |
| Baker, JV | 1 |
| Migueles, SA | 1 |
| Sereti, I | 1 |
| Özdener-Poyraz, AE | 1 |
| Vaidean, G | 1 |
| Santos Junior, GGD | 1 |
| Araújo, PSR | 1 |
| Leite, KME | 1 |
| Godoi, ET | 1 |
| Vasconcelos, AF | 1 |
| Lacerda, HR | 1 |
| Pyarali, F | 1 |
| Iordanov, R | 1 |
| Ebner, B | 1 |
| Grant, J | 1 |
| Vincent, L | 1 |
| Toirac, A | 1 |
| Haque, T | 1 |
| Zablah, G | 1 |
| Kapoor, K | 1 |
| Powell, A | 1 |
| Boulanger, C | 1 |
| Hurwitz, B | 1 |
| Alcaide, M | 1 |
| Martinez, C | 1 |
| Mwangi, L | 2 |
| Chigonda, TG | 1 |
| Chatora, GT | 1 |
| Ngwende, GW | 1 |
| Miller, RF | 1 |
| Ferrand, RA | 1 |
| Falcinelli, E | 1 |
| Francisci, D | 1 |
| Schiaroli, E | 1 |
| Minuz, P | 1 |
| Orsini, S | 1 |
| Malincarne, L | 1 |
| Sebastiano, M | 1 |
| Mezzasoma, AM | 1 |
| Pasticci, MB | 1 |
| Guglielmini, G | 1 |
| Baldelli, F | 1 |
| Gresele, P | 1 |
| Mageau, A | 1 |
| Rodriguez-Régent, C | 1 |
| Dion, J | 1 |
| Dupin, N | 1 |
| Mouthon, L | 1 |
| Le Jeunne, C | 1 |
| Régent, A | 1 |
| Birse, K | 1 |
| Cheruiyot, J | 1 |
| Akolo, M | 1 |
| Mungai, J | 1 |
| Romas, L | 1 |
| Mutch, S | 1 |
| Burgener, A | 1 |
| Maggi, P | 3 |
| De Socio, GV | 3 |
| Cicalini, S | 2 |
| D'Abbraccio, M | 2 |
| Dettorre, G | 2 |
| Di Biagio, A | 2 |
| Martinelli, C | 3 |
| Nunnari, G | 2 |
| Rusconi, S | 2 |
| Sighinolfi, L | 2 |
| Spagnuolo, V | 2 |
| Squillace, N | 2 |
| Zafar, MU | 1 |
| Rodriguez, JC | 1 |
| Okoroafor, I | 1 |
| Heyison, A | 1 |
| Cavanagh, K | 2 |
| Rodriguez-Caprio, G | 1 |
| Weinberg, A | 1 |
| Escolar, G | 1 |
| Badimon, JJ | 1 |
| O'Brien, M | 1 |
| Montenont, E | 1 |
| Hu, L | 1 |
| Nardi, MA | 1 |
| Valdes, V | 1 |
| Merolla, M | 1 |
| Gettenberg, G | 1 |
| Bhardwaj, N | 1 |
| Berger, JS | 1 |
| Ayers, J | 1 |
| Mandell, R | 1 |
| Sanghvi, K | 1 |
| Aboujaoude, R | 1 |
| Hsi, DH | 1 |
| Park, TE | 1 |
| Yusuff, J | 1 |
| Sharma, R | 1 |
| Okeke, NL | 1 |
| Chin, T | 1 |
| Clement, M | 1 |
| Chow, SC | 1 |
| Hicks, CB | 1 |
| Ricci, E | 1 |
| Parruti, G | 1 |
| Calza, L | 1 |
| Celesia, BM | 1 |
| Orofino, G | 1 |
| Madeddu, G | 1 |
| Menzaghi, B | 1 |
| Taramasso, L | 1 |
| Penco, G | 1 |
| Carenzi, L | 1 |
| Franzetti, M | 1 |
| Bonfanti, P | 1 |
| Hauguel-Moreau, M | 1 |
| Boccara, F | 2 |
| Boyd, A | 1 |
| Salem, JE | 1 |
| Brugier, D | 1 |
| Curjol, A | 1 |
| Hulot, JS | 1 |
| Kerneis, M | 1 |
| Galier, S | 1 |
| Cohen, A | 2 |
| Montalescot, G | 1 |
| Collet, JP | 1 |
| Silvain, J | 1 |
| Durosinmi, MA | 1 |
| Armistead, H | 1 |
| Akinola, NO | 1 |
| Onayemi, O | 1 |
| Adediran, IA | 1 |
| Olasode, OA | 1 |
| Elujoba, AA | 1 |
| Irinoye, O | 1 |
| Ogun, SA | 1 |
| Odusoga, OL | 1 |
| Falola, OL | 1 |
| Muraina, HA | 1 |
| Nayeb-Hashemi, H | 1 |
| Kaunitz, JD | 1 |
| Tornero, C | 1 |
| Ventura, A | 1 |
| Mafe, M | 1 |
| Stanley, A | 1 |
| Levin, C | 1 |
| Heckmann, JM | 1 |
| Burkholder, GA | 1 |
| Tamhane, AR | 1 |
| Salinas, JL | 1 |
| Mugavero, MJ | 1 |
| Raper, JL | 1 |
| Westfall, AO | 1 |
| Saag, MS | 1 |
| Willig, JH | 1 |
| Giallauria, F | 1 |
| Paragliola, T | 1 |
| Del Forno, D | 1 |
| Baiano, A | 1 |
| de Cristofaro, A | 1 |
| Rossi, M | 1 |
| Vigorito, C | 1 |
| Ernst, J | 1 |
| Barbaro, G | 1 |
| Di Lorenzo, G | 1 |
| Barbarini, G | 1 |
| Solensky, R | 1 |
| Shen, YM | 1 |
| Frenkel, EP | 1 |
| Ball, SC | 1 |
| Velez, AP | 1 |
| Menezes, L | 1 |
| Crespo, A | 1 |
| Cao, YJ | 1 |
| Caffo, B | 1 |
| Choi, L | 1 |
| Radebaugh, CL | 1 |
| Fuchs, EJ | 1 |
| Hendrix, CW | 1 |
| Pankhurst, CL | 1 |
| Lewis, DA | 1 |
| Clark, DT | 1 |
| Macilwain, C | 1 |
| Armistead, HS | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effect of Aspirin on HIV Disease Progression Among HIV- Infected Individuals Initiating Anti- Retroviral Therapy[NCT05525156] | Phase 2 | 454 participants (Anticipated) | Interventional | 2020-03-02 | Suspended (stopped due to The study stopped due to expiry of study drugs) | ||
| Limiting HIV Target Cells by Inducing Immune Quiescence in the Female Genital Tract[NCT02079077] | 91 participants (Actual) | Interventional | 2014-04-30 | Completed | |||
| Intensified Tuberculosis Treatment to Reduce the Mortality of HIV-infected and Uninfected Patients With Tuberculosis Meningitis: a Phase III Randomized Controlled Trial (Acronym: INTENSE-TBM)[NCT04145258] | Phase 3 | 768 participants (Anticipated) | Interventional | 2021-02-07 | Recruiting | ||
| Targeting Platelets in Chronic HIV Infection[NCT02578706] | Phase 2 | 27 participants (Actual) | Interventional | 2015-10-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
We will measure changes in the number of CD4+T cells expressing CCR5 at the female genital tract before and at the end of the study. (NCT02079077)
Timeframe: baseline and 8 weeks
| Intervention | percentage of cells (Median) |
|---|---|
| Acetylsalicylic Acid (ASA) | 17.60 |
| Hydroxychloroquine (HCQ) | 22.10 |
We will analyse reduce of immune activation by measuring change in T cell activation (CD69) between baseline and every month during drug administration phase (8 weeks). (NCT02079077)
Timeframe: Baseline and 8 weeks
| Intervention | percentage of cells (Mean) | |
|---|---|---|
| Average of CD4+CD69+ at baseline | Average of CD4+CD69+ T cells cells after treatment | |
| Acetylsalicylic Acid (ASA) | 4.04 | 4.9 |
| Hydroxychloroquine (HCQ) | 5.55 | 4.99 |
Alpha angle is measured using thromboelastography, measured by a tangent to the clotting curve through the 2mm point (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | degree (Mean) |
|---|---|
| Aspirin and Placebo | 0.00 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.50 |
The classical monocyte is characterized by high level expression of the CD14 cell surface receptor (CD14++ CD16- monocyte) (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | -0.09 |
| Clopidogrel and Placebo | -0.12 |
| Placebo Only | -0.04 |
Clot formation time is measured using thromboelastography. time from 2 to 20 mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | -1.00 |
| Clopidogrel and Placebo | 2.00 |
| Placebo Only | 1.63 |
Clot formation kinetics, or coagulation time, is measured using thromboelastography. time to 2mm amplitude in seconds. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | seconds (Mean) |
|---|---|
| Aspirin and Placebo | 3.00 |
| Clopidogrel and Placebo | 1.00 |
| Placebo Only | -13.13 |
D-Dimer level looks at coagulation of blood. D-dimers are not normally present in blood except when coagulation has occurred. (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | mcg/L (Mean) |
|---|---|
| Aspirin and Placebo | -295.99 |
| Clopidogrel and Placebo | 151.96 |
| Placebo Only | 1109.38 |
Interleukin 6 gene encodes a cytokine that functions in inflammation and implicated in a variety of inflammatory-associated disease states. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -0.36 |
| Clopidogrel and Placebo | 0.02 |
| Placebo Only | 0.85 |
The intermediate monocyte with high level expression of CD14 and low level expression of CD16 (CD14++CD16+ monocytes). (NCT02578706)
Timeframe: Baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.02 |
| Clopidogrel and Placebo | 0.06 |
| Placebo Only | 0.04 |
Maximum Clot Firmness (MCF) is measured using thromboelastography. maximum ampliture in mm (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | mm (Mean) |
|---|---|
| Aspirin and Placebo | 1.38 |
| Clopidogrel and Placebo | 1.20 |
| Placebo Only | 0.38 |
Soluble CD163 is a specific macrophage activation marker, associated with morphological disease grade. A high sCD163 indicates more disease. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 26.88 |
| Clopidogrel and Placebo | 15.8 |
| Placebo Only | -63.38 |
Change in % platelet monocyte aggregates from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet monocyte aggregates (Mean) |
|---|---|
| Aspirin and Placebo | 10.55 |
| Clopidogrel and Placebo | 3.88 |
| Placebo Only | 8.96 |
The non-classical monocyte shows low level expression of CD14 and additional co-expression of the CD16 receptor (CD14+CD16++ monocyte).[ (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | 10^3 cells/µl (Mean) |
|---|---|
| Aspirin and Placebo | 0.002 |
| Clopidogrel and Placebo | 0.03 |
| Placebo Only | -0.03 |
Change in % platelet aggregation in response to stimulation by Adenosine Diphosphate (ADP) from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -7.25 |
| Clopidogrel and Placebo | -32.40 |
| Placebo Only | -6.50 |
Change in % platelet aggregation in response to stimulation by arachidonic acid 1500µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -53.33 |
| Clopidogrel and Placebo | -31.00 |
| Placebo Only | -13.25 |
Change in % platelet aggregation in response to stimulation by Collagen 2µg/mL from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -40.37 |
| Clopidogrel and Placebo | -9.60 |
| Placebo Only | 8.62 |
Change in % platelet aggregation in response to stimulation by light transmission aggregometry as measured by epinephrine 5µM from baseline to week 24 (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet aggregation (Mean) |
|---|---|
| Aspirin and Placebo | -35.25 |
| Clopidogrel and Placebo | -21.40 |
| Placebo Only | -10.63 |
Soluble CD14 (sCD14) levels in blood. sCD14 is a nonspecific maker of monocyte activation. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | 35.75 |
| Clopidogrel and Placebo | -251.40 |
| Placebo Only | -101.75 |
Soluble CD40-ligand levels (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/mL (Mean) |
|---|---|
| Aspirin and Placebo | -28.05 |
| Clopidogrel and Placebo | -25.68 |
| Placebo Only | 13.65 |
Change in spontaneous % platelet from baseline to week 24. Spontaneous platelet aggregation? (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | % platelet (Mean) |
|---|---|
| Aspirin and Placebo | -0.75 |
| Clopidogrel and Placebo | -0.60 |
| Placebo Only | -0.88 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 137.77 |
| Clopidogrel and Placebo | 59.46 |
| Placebo Only | 19.78 |
Soluble tumor necrosis factor receptor (sTNFR) serum concentration (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | pg/ml (Mean) |
|---|---|
| Aspirin and Placebo | 283.13 |
| Clopidogrel and Placebo | 347.00 |
| Placebo Only | 4.25 |
substudy - Change in thrombus formation by Badimon chamber (high shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. The high shear chambers (inner lumen diameter 0.1 mm, Reynolds number 60, shear rate 1690 s- 1) mimic the rheologic conditions of a moderately stenosed coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -3052.20 |
| Clopidogrel and Placebo | -2798.80 |
| Placebo Only | -753.00 |
substudy - Change in thrombus formation by Badimon chamber (low shear) from baseline to 24 weeks. Thrombus formation on a blood vessel measured by immunohistochemistry staining of tissue cross sections. μ(2)/mm is the area of thrombus. The low shear chamber (inner lumen diameter 0.2 mm, Reynolds number 30, shear rate 500 s- 1) simulates flow conditions of a normal coronary artery. (NCT02578706)
Timeframe: baseline and 24 weeks
| Intervention | μ(2)/mm (Mean) |
|---|---|
| Aspirin and Placebo | -1036 |
| Clopidogrel and Placebo | -899.20 |
| Placebo Only | -203.75 |
Safety as measured by a Summary of the number of subjects with at least one grade 3 or higher sign/symptom or laboratory abnormality. A grade 3 sign/symptom was defined as medically significant but not immediately life threatening. (NCT02578706)
Timeframe: 24 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| Aspirin and Placebo | 0 |
| Clopidogrel and Placebo | 1 |
| Placebo Only | 0 |
8 reviews available for aspirin and HIV Coinfection
| Article | Year |
|---|---|
Preventing HIV infection without targeting the virus: how reducing HIV target cells at the genital tract is a new approach to HIV prevention.
Topics: Aspirin; Disease Susceptibility; Female; Genitalia, Female; HIV Infections; HIV Seronegativity; HIV- | 2017 |
Statins and aspirin in the prevention of cardiovascular disease among HIV-positive patients between controversies and unmet needs: review of the literature and suggestions for a friendly use.
Topics: Adult; Aged; Aspirin; Cardiovascular Diseases; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Red | 2019 |
Gastroduodenal mucosal defense.
Topics: Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Bicarbonates; Duodenum; Gastric Mucosa; Helicobact | 2009 |
Alternative treatment modalities in human immunodeficiency virus/acquired immune deficiency syndrome.
Topics: Administration, Topical; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Complementary Therapies; | 2003 |
Coronary artery disease and stroke in HIV-infected patients: prevention and pharmacological therapy.
Topics: Anticoagulants; Antiretroviral Therapy, Highly Active; Aspirin; Cardiomyopathies; Comorbidity; Coron | 2003 |
Drug allergy: desensitization and treatment of reactions to antibiotics and aspirin.
Topics: Anti-Bacterial Agents; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Dese | 2004 |
Thrombosis and a hypercoagulable state in HIV-infected patients.
Topics: Adult; Antibodies, Antiphospholipid; Anticoagulants; Antiretroviral Therapy, Highly Active; Aspirin; | 2004 |
Taking the HIV factory tour.
Topics: Anti-HIV Agents; Aspirin; CD4-Positive T-Lymphocytes; HIV; HIV Infections; Humans; NF-kappa B; Selen | 2001 |
13 trials available for aspirin and HIV Coinfection
| Article | Year |
|---|---|
Effect of aspirin on HIV disease progression among HIV-infected individuals initiating antiretroviral therapy: study protocol for a randomised controlled trial.
Topics: Adult; Anti-Retroviral Agents; Aspirin; CD4 Lymphocyte Count; Disease Progression; HIV Infections; H | 2021 |
Intensified tuberculosis treatment to reduce the mortality of HIV-infected and uninfected patients with tuberculosis meningitis (INTENSE-TBM): study protocol for a phase III randomized controlled trial.
Topics: Adolescent; Adult; Antitubercular Agents; Aspirin; Clinical Trials, Phase III as Topic; HIV Infectio | 2022 |
A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.
Topics: Antitubercular Agents; Aspirin; HIV; HIV Infections; Humans; Linezolid; Rifampin; Treatment Outcome; | 2023 |
A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.
Topics: Antitubercular Agents; Aspirin; HIV; HIV Infections; Humans; Linezolid; Rifampin; Treatment Outcome; | 2023 |
A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.
Topics: Antitubercular Agents; Aspirin; HIV; HIV Infections; Humans; Linezolid; Rifampin; Treatment Outcome; | 2023 |
A Phase 2A Trial of the Safety and Tolerability of Increased Dose Rifampicin and Adjunctive Linezolid, With or Without Aspirin, for Human Immunodeficiency Virus-Associated Tuberculous Meningitis: The LASER-TBM Trial.
Topics: Antitubercular Agents; Aspirin; HIV; HIV Infections; Humans; Linezolid; Rifampin; Treatment Outcome; | 2023 |
Pro-inflammatory and pro-resolving lipid mediators of inflammation in HIV: effect of aspirin intervention.
Topics: Aspirin; Cardiovascular Diseases; Eicosanoids; HIV Infections; Humans; Inflammation; Inflammation Me | 2023 |
An open label randomized controlled trial of atorvastatin versus aspirin in elite controllers and antiretroviral-treated people with HIV.
Topics: Anti-Retroviral Agents; Aspirin; Atorvastatin; Cardiovascular Diseases; CD4 Lymphocyte Count; Female | 2023 |
The Effect of Atorvastatin + Aspirin on the Endothelial Function Differs with Age in Patients with HIV: A Case-Control Study.
Topics: Aspirin; Atorvastatin; Brachial Artery; Carotid Arteries; Carotid Intima-Media Thickness; Case-Contr | 2021 |
Effect of aspirin treatment on abacavir-associated platelet hyperreactivity in HIV-infected patients.
Topics: Anti-HIV Agents; Aspirin; Blood Platelets; Cohort Studies; Cross-Over Studies; Dideoxynucleosides; D | 2018 |
Using safe, affordable and accessible non-steroidal anti-inflammatory drugs to reduce the number of HIV target cells in the blood and at the female genital tract.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Female; Genitalia, Female; HIV Infections; | 2018 |
Targeting thrombogenicity and inflammation in chronic HIV infection.
Topics: Adult; Anti-Inflammatory Agents; Antiretroviral Therapy, Highly Active; Aspirin; Biomarkers; Blood P | 2019 |
Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study.
Topics: Adenosine Diphosphate; Adult; Aged; Anti-HIV Agents; Arachidonic Acid; Aspirin; Cells, Cultured; Col | 2013 |
Selenium and aspirin in people living with HIV and AIDS in Nigeria.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Aspirin; Black People; Body Weight; CD4 | 2008 |
Prophylactic application of an intra-alveolar socket medicament to reduce postextraction complications in HIV-seropositive patients.
Topics: Acquired Immunodeficiency Syndrome; Adult; Anesthetics, Local; Aspirin; Chlortetracycline; Dental Ca | 1994 |
Salasalate for HIV.
Topics: Aspirin; Double-Blind Method; HIV Infections; Humans; Inflammation; Placebos | 1995 |
24 other studies available for aspirin and HIV Coinfection
| Article | Year |
|---|---|
For which HIV Patients Aspirin and Statins are Good?
Topics: Aspirin; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Risk Factors | 2021 |
Low-Dose Acetylsalicylic Acid Reduces T Cell Immune Activation: Potential Implications for HIV Prevention.
Topics: Adult; Anti-Inflammatory Agents; Aspirin; Biomarkers; Cytokines; Female; HIV Infections; Humans; Imm | 2021 |
Preventive Cardiovascular Care in Patients With HIV Infection in an Outpatient Clinic.
Topics: Ambulatory Care Facilities; Aspirin; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Reductase Inh | 2022 |
Cardiovascular disease and prevention among people living with HIV in South Florida.
Topics: Adult; Aged; Aged, 80 and over; Aspirin; Cardiovascular Diseases; Female; Florida; Heart Disease Ris | 2021 |
Extensive cerebrovascular disease and stroke with prolonged prodromal symptoms as first presentation of perinatally-acquired human immunodeficiency virus infection in a young adult.
Topics: Adult; Aspirin; Basilar Artery; Cerebrovascular Disorders; Computed Tomography Angiography; Delayed | 2018 |
Treatment of Syphilis-Associated Cerebral Vasculitis: Reappearance of an Old Question.
Topics: Adrenal Cortex Hormones; Anti-Bacterial Agents; Anti-Inflammatory Agents; Antiretroviral Therapy, Hi | 2018 |
Acute coronary thrombosis and multiple coronary aneurysms in a 22-year-old man with the human immunodeficiency virus.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Aspirin; Clopidogrel; Coronary Aneurysm; Coronary An | 2014 |
Use of aspirin and statins for the primary prevention of myocardial infarction and stroke in patients with human immunodeficiency virus infection.
Topics: Aged; Aspirin; Cross-Sectional Studies; Female; HIV Infections; Humans; Hydroxymethylglutaryl-CoA Re | 2016 |
Coronary artery disease risk reduction in HIV-infected persons: a comparative analysis.
Topics: Adult; Aspirin; Case-Control Studies; Coronary Artery Disease; Drug Prescriptions; Female; HIV Infec | 2016 |
Study says daily PrEP use is as safe as aspirin.
Topics: Anti-HIV Agents; Aspirin; Chemoprevention; HIV Infections; Humans | 2016 |
Statins and Aspirin use in HIV-infected people: gap between European AIDS Clinical Society guidelines and clinical practice: the results from HIV-HY study.
Topics: Adolescent; Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Cardiovascular Diseases; | 2016 |
Platelet reactivity in human immunodeficiency virus infected patients on dual antiplatelet therapy for an acute coronary syndrome: the EVERE2ST-HIV study.
Topics: Acute Coronary Syndrome; Adenosine; Anti-HIV Agents; Aspirin; Blood Platelets; Clopidogrel; Cross-Se | 2017 |
Use of statins and aspirin to prevent cardiovascular disease among HIV-positive patients. A survey among Italian HIV physicians.
Topics: Aspirin; Cardiovascular Diseases; Data Collection; HIV Infections; Humans; Hydroxymethylglutaryl-CoA | 2017 |
Aspirin is indicated for primary prevention of cardiovascular events in HIV-infected patients.
Topics: Aged; Aspirin; Cardiovascular Diseases; Chemoprevention; Female; HIV Infections; Humans; Male; Middl | 2010 |
The complexity of HIV vasculopathy.
Topics: Adult; Aspirin; Cytomegalovirus Infections; Female; HIV Infections; Humans; Infarction, Middle Cereb | 2012 |
Underutilization of aspirin for primary prevention of cardiovascular disease among HIV-infected patients.
Topics: Aged; Aspirin; Cross-Sectional Studies; Drug Utilization; Female; Heart Diseases; HIV Infections; Hu | 2012 |
[Cardiac rehabilitation in a HIV-patient treated with protease inhibitors].
Topics: Adult; Aspirin; Carbazoles; Carvedilol; Cholesterol; Coronary Angiography; Diet Therapy; Drug Therap | 2003 |
Kawasaki-like syndrome in an HIV-infected adult.
Topics: Adult; Anti-Inflammatory Agents; Antiretroviral Therapy, Highly Active; Aspirin; Drug Therapy, Combi | 2003 |
Kawasaki-like disease in an HIV-infected patient.
Topics: Adult; Anti-Infective Agents; Anti-Inflammatory Agents, Non-Steroidal; Aspirin; Child, Preschool; Fe | 2005 |
Kawasaki-like syndrome possibly associated with immune reconstitution inflammatory syndrome in an HIV-positive patient.
Topics: Anti-HIV Agents; Aspirin; Drug Therapy, Combination; HIV Infections; Humans; Immune System Diseases; | 2006 |
Noninvasive quantitation of drug concentration in prostate and seminal vesicles: improvement and validation with desipramine and aspirin.
Topics: Administration, Oral; Adolescent; Adult; Algorithms; Aspirin; Bayes Theorem; Biomarkers, Pharmacolog | 2008 |
Aspirin on trial in the battle against AIDS.
Topics: Aspirin; Clinical Trials as Topic; HIV Infections; Humans | 1994 |
Aspirin on trial as HIV treatment.
Topics: Aspirin; HIV Infections; Humans | 1993 |
New AIDS drug leaps over the counter.
Topics: Aspirin; HIV Infections; Humans | 1993 |